BioMarker Strategies Awarded $1.5 Million National Cancer Institute Contract to Develop Companion Diagnostic Test to Select Optimal Therapy for Melanoma Patients
9/25/2013 9:43:04 AM
BALTIMORE--(BUSINESS WIRE)--BioMarker Strategies today announced that the National Cancer Institute (NCI) has awarded the company a $1.5 million Small Business Innovative Research (SBIR) Phase II contract to develop PathMAP™, a pathway-based companion diagnostic test to facilitate the selection of optimal therapy for individual patients with melanoma.
Help employers find you! Check out all the jobs and post your resume.
comments powered by